Dermata Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on July 15, 2025. During the meeting, Mary Fisher and Andrew Sandler M.D. were elected as Class I directors. The appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The issuance of shares of the Company's common stock underlying certain warrants was approved. An amendment to effect a reverse stock split of the issued and outstanding shares of Common Stock was also approved. Additionally, the proposal to adjourn the meeting if there were insufficient votes to approve certain proposals was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.